Published Date: 16 Feb 2023
A divided U.S. appeals court ruled on Tuesday that federal workers generally do not deserve extra pay for being exposed to the COVID-19 virus on the job.
Read Full NewsBritish lawmakers rejected on Friday a proposal to legalise assisted dying for terminally ill people, dealing a major setback to campaigners and bringing the latest effort...
In a global review, legalization was associated with increased cannabis use and related emergency department visits, with potential decreases in the use of alcohol and tobacco.
Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.
Patients who respond to neoadjuvant immunochemotherapy may be able to undergo less extensive surgery, with high rates of disease control and organ preservation.
In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.
For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.
1.
Review looks at potential treatment targets in the tumor microenvironment.
2.
Patellar Resurfacing in Total Knee Replacement; Patient Messaging Trends
3.
Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC
4.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
5.
PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.
1.
Learning from Uncommon Inherited Bleeding Disorder Presentations
2.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
3.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
4.
Emerging Therapies Using Combination Radiopharmaceutical Platforms for Sequential Tumor Targeting
5.
Pediatric Hematopoietic Development Across Childhood
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
3.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
4.
Common Cancer Myths Debunked
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation